Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientif...(the overall percent weight loss in the E...),Health

Also included in the presentation were discontinuation rates for cognitive events. Overall, these rates were low and the events were generally mild to moderate and reversible with discontinuation of treatment. There was one severe event in the treatment arm and one in the placebo arm that led to discontinuation. Specifically, the discontinuation rates for various cognitive-related events were as follows:

    % of Patients             EQUIP (n=1,264)           CONQUER (n=2,485)
    -------------       ------------------------    -------------------------
    MedDRA Preferred               Qnexa   Qnexa               Qnexa    Qnexa
     Terms              Placebo     Low     Full    Placebo     Mid     Full
    ----------------    -------    -----   -----    -------    -----    -----
    Disturbance in
     Attention             0.4%     0.0%     1.4%      0.1%     0.0%     0.7%
    Memory Impairment      0.0%     0.0%     0.0%      0.1%     0.0%     0.5%
    Amnesia
     (forgetfulness)       0.2%     0.0%     0.6%      0.0%     0.2%     0.3%
    Aphasia (word
     finding
     difficulties)         0.0%     0.0%     0.2%      0.0%     0.0%     0.3%
    Cognitive Disorder     0.2%     0.0%     0.0%      0.0%     0.0%     0.2%
    Confusional State      0.0%     0.4%     0.2%      0.1%     0.2%     0.1%
    Bradyphrenia
     (slow thinking)       0.0%     0.0%     0.2%      0.0%     0.0%     0.0%
    Disorientation         0.0%     0.0%     0.0%      0.0%     0.0%     0.0%
    Mental Impairment      0.0%     0.0%     0.0%      0.0%     0.0%     0.0%

    Events are not additive as some patients have reported more than one event
    leading to study drug discontinuation.

Consistent with standard scientific and regulatory methodologies, these infrequent events that lead to study drug discontinuati
'/>"/>